Status:
COMPLETED
Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborating Sponsors:
Rutgers University
Conditions:
Central Nervous System Lymphoma
Eligibility:
All Genders
18-80 years
Brief Summary
The purpose of this study is to test resting state functional Magnetic Resonance Imaging (rsfMRI) scans to see if rsfMRI scans are better than the standard task based fMRI scans at diagnosing or monit...
Eligibility Criteria
Inclusion
- Immunocompetent patients with newly diagnosed or recurrent non-Hodgkins lymphoma involving the brain (primary or secondary), as demonstrated by MRI and histologic confirmation either by positive CSF cytology for lymphoma or a monoclonal lymphocyte population defined by cell surface markers, vitreous or uvea biopsy or brain biopsy
- Age 18-80 years
- Treatment plan for HDC-ASCT
- Fluent in English
- Patients who in the judgment of the investigators and/or consenting professional, are able to understand the purpose of the study and provide informed consent will be included.
Exclusion
- Claustrophobia
- Any contraindication to the use of contrast and/or general guidelines for MR imaging as per standard Department of Radiology imaging guidelines
- Unable to cooperate for MRI
Key Trial Info
Start Date :
November 7 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 4 2022
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT03342586
Start Date
November 7 2017
End Date
August 4 2022
Last Update
August 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065